AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across various therapeutic areas. The company's mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution. AbbVie intends to execute its strategy and advance its mission by maximizing the benefits of a diversified revenue base with multiple long-term growth drivers, leveraging its commercial strength and international infrastructure across therapeutic areas, and ensuring strong commercial execution of new product launches. The company continues to invest in and expand its pipeline to support opportunities in immunology, oncology, aesthetics, neuroscience, and eye care, as well as invest in key on-market products. AbbVie anticipates several regulatory submissions and data readouts from key clinical trials in the next 12 months, which are critical for maintaining operational flexibility and adapting to market changes. The financial performance in 2023 included delivering worldwide net revenues of $54.3 billion, with a focus on generating substantial operating cash flows to support investment in innovative research and development. AbbVie’s strategy has focused on delivering strong financial results while ensuring a strong, sustainable growth business over the long term, which reflects the company's ability to maintain positive adjustment under challenging conditions. The company’s financial results were impacted by external pressures, including competition from biosimilars, which necessitated effective risk management and strategic response to mitigate revenue erosion. AbbVie continues to pursue strategies to maintain broad formulary access and manage the impact of biosimilar erosion, demonstrating its commitment to organizational resilience. The company engages in collaborative, licensing, and other arrangements that may require future milestone payments, reflecting its adaptability and strategic foresight in navigating complex situations. AbbVie’s ability to generate cash flows from operations and attract long-term capital is essential for supporting its growth objectives and ensuring organizational survival in a turbulent market environment. The company monitors economic conditions and the creditworthiness of customers to mitigate credit risk, which is integral to maintaining operational continuity. AbbVie’s commitment to research and innovation is underscored by its extensive pipeline, which includes approximately 90 compounds in development, demonstrating its focus on resilience strategies that enable recovery and transformation in response to market demands. The company’s strategic initiatives are designed to enhance its competitive advantage and ensure organizational effectiveness in the face of environmental disruptions. AbbVie’s operational management practices emphasize performance maintenance and resource allocation to adapt to unexpected situations, thereby reinforcing its organizational strength and agility in a dynamic business landscape.